Query String: Atorvastatin
Atorvastatin Calcium Atorvastatin BDBM50442868
BDBM50420200 ATORVASTATIN
Calcium (betaR,deltaR)-2-(p-fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoate (1:2) CHEMBL393220 US9006282, Atorvastatin calcium bis{(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate} BDBM50221993 atorvastatin calcium
Atorvastatin lactone 5-(4-Fluoro-phenyl)-1-[2-(4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide BDBM50011032 US9006282, Example 3, Compound 2 CHEMBL333687
CI 981 (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid Lipitor CHEMBL1487 Atorvastatin (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid US9353061, Atorvastatina BDBM22164
- Lindsay, D; Jackson, P; Hindley, S; Bhamra, I Rosuvastatin and atorvastatin derivatives US Patent US9006282 (2015)
- Taldone, T; Zito, SW; Talele, TT Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin. Bioorg Med Chem Lett 18: 479-84 (2008)
- Staedler, D; Chapuis-Bernasconi, C; Dehmlow, H; Fischer, H; Juillerat-Jeanneret, L; Aebi, JD Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem 55: 4990-5002 (2012)
- Wang, Z; Cheng, L; Kai, Z; Wu, F; Liu, Z; Cai, M Molecular modeling studies of atorvastatin analogues as HMGR inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations. Bioorg Med Chem Lett 24: 3869-76 (2014)
- ChEMBL_1871101 (CHEMBL4372268) Inhibition of human CYP3A4 using atorvastatin as substrate
- ChEMBL_689765 (CHEMBL1635605) Inhibition of CYP3A4 in human liver microsomes using atorvastatin as probe
- ChEMBL_1687642 (CHEMBL4038121) Inhibition of atorvastatin PEG-fluorescein binding to PDEdelta (unknown origin) by fluorescence polarization assay
- ChEMBL_2476088 Displacement of fluorescein-labeled Atorvastatin from PDEdelta (unknown origin) assessed as dissociation constant incubated for 10 hrs by fluorescence anisotropy
- ChEMBL_1889156 (CHEMBL4390910) Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis
- ChEMBL_1493572 (CHEMBL3529386) Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis
- ChEMBL_2476030 Displacement of fluorescein-labeled Atorvastatin from N-terminal His6 tagged human recombinant PDE6D extracted from Escherichia coli BL21 star (DE3) pLysS assessed as dissociation constant by fluorescence polarization assay
- ChEMBL_1493640 (CHEMBL3530056) Metabolism-dependent inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis
- Fluorescence Polarization Assay Binding to PDEδ was validated and quantified by means of a displacement assay employing a fluorescent-tagged analog of the HMG-CoA reductase inhibitor Atorvastatin (Lipitor ) which has previously been shown to also bind to PDEδ. The KD values were determined by the Fluorescence polarization competition binding assay previously developed by the inventors (Nature 2013, 497, 638).